Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...

The data raise questions about valve hemodynamics and the role of early imaging to stay ahead of clinical and subclinical ...

Recent research from Karl Landsteiner University of Health Sciences (KL Krems) provides important new insights into how ...

DurAVR ® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm 2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler ...

Medtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.

In patients with aortic stenosis and a small aortic annulus, results showed comparable composite outcome of mortality, disabling stroke, and heart failure hospitalization, and continued superior ...

Medtronic plc MDT recently unveiled two-year Small Annuli Randomized to Evolut or SAPIEN (“SMART”) Trial results at the Cardiovascular Research Technologies (“CRT”) 2025 conference in Washington, D.C.

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...